AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients out in Nature Communications nature.com/articles/s4146… This study introduces a custom circulating tumor DNA (ctDNA) 🧬sequencing assay, AR-ctDETECT, designed to

It is this time of the Year again: 10 TOP TRANSLATIONAL PAPERS IN GU ONCOLOGY! 1/ Prostate Paper 1 Fonseca et al. introduced a machine-learning approach that predicts whether patients with #mCRPC have sufficient ctDNA% for informative genotyping. This study addresses a critical

PROSTATE Paper 2 Franseschini et al. developed a targeted DNA methylation assay for the detection of neuroendocrine prostate cancer using plasma cell-free DNA with an AUC > 0.93. Their assay also quantifies tumor content and offers a phenotype evidence score, which reflects

PROSTATE Paper 3 Knutson et al. developed the AR-ctDETECT assay to detect ctDNA in limiting plasma cfDNA from pts w/ #mCRPC in Alliance for Clinical Trials in Oncology A031201 ph3 trial of enzalutamide w/ or w/o abiraterone. The ctDNA assay was able to prognosticate outcomes, as pts w/ mCRPC who were

The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Different FOXA1 classes have different biologic behaviors, clinical outcomes & racial clustering, esp. Class 1B and 2. @UMNcancer Scott Dehm aacrjournals.org/clincancerres/…

In memory of Dr. Felix Feng. Thank you European Urology for honoring our beloved colleague and friend, gone too soon. We miss you Felix Mary Feng Nancy Lin, MD PCF Science sciencedirect.com/science/articl…

Excited to share a new paper by postdoc Dr. Kiel Tietz Masonic Cancer Center, University of Minnesota! CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells: Cell Reports cell.com/cell-reports/f… Work funded by CDMRP and @NCICancerBio

Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis of circulating tumor cells! Led by the brilliant Marina Sharifi and Jamie Sperger AACR Funded by PCF Science NIH CDMRP

🧪 Dr. Scott Dehm and collaborators including Huang Lab, Emmanuel Antonarakis, & Misha Beltran showed that double-negative #CRPC cells express genes defining basal, club, and hillock epithelial cells from benign #prostate. PNASNews | bit.ly/4gI7fH3

Check out our new work exploring AR biology in advanced prostate cancer: tinyurl.com/2s39jh8b. We found that tumours expressing a specific AR variant (ARv567es) have a distinct transcriptomic profile and are resistant to androgen deprivation and bipolar androgen therapy

Fascinating work by Chen et al in uncovering new metabolomics of SPOP-mutant prostate cancer, we review here Emmanuel Antonarakis Scott Dehm nature.com/articles/s4301…

Can anyone top the Halabi model for predicting survival in mCRPC? Yes! Dr Halabi does it again! See our ctDNA based clinical-genetic model in first line ARPI treatment out today in European Urology: sciencedirect.com/science/articl… Scott Dehm DCI Center for Prostate & Urologic Cancers Duke Cancer Prostate Cancer Foundation

It was a sheer pleasure to have Adam Sharp here in Minnesota delivering a Cancer Center Seminar lecture about manipulation of the apoptosis pathway for prostate cancer therapeutics. Thanks Scott Dehm for inviting and hosting him. Let the collaborations begin! Masonic Cancer Center, University of Minnesota